CASC19: An Oncogenic Long Non-coding RNA in Different Cancers.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• CASC19 is a 324 bp long non-coding RNA located on chromosome 8q24.21.
• Emerging research links CASC19 to tumor prognosis and radiation tolerance mechanisms in cancer radiotherapy.
• Dysregulation of CASC19 is implicated in various cancers and diseases.

Purpose of the Study:

• To review the multifaceted roles and alterations of CASC19 in diverse malignancies and conditions.
• To explore CASC19's potential as a therapeutic target and prognostic biomarker.
• To highlight CASC19's significance in modulating radiotherapy efficacy.

Main Methods:

• Literature review of studies investigating CASC19 expression and function.
• Analysis of CASC19's involvement in tumor development and progression.
• Examination of CASC19's impact on radiation tolerance and treatment outcomes.

Main Results:

• CASC19 expression is altered in nasopharyngeal carcinoma, cervical cancer, colorectal cancer, non-small cell lung cancer, clear cell renal cell carcinoma, gastric cancer, pancreatic cancer, hepatocellular carcinoma, glioma, and osteoarthritis.
• CASC19 regulatory networks are critical for tumor initiation and progression.
• CASC19 expression levels serve as predictive markers for prognosis and treatment response, particularly in radiotherapy.

Conclusions:

• CASC19 represents a promising target for novel therapeutic strategies in oncology.
• Understanding CASC19's regulatory networks is vital for advancing cancer treatment.
• CASC19 plays a key role in determining radiotherapy efficacy, offering potential for improved treatment success rates.
• Further investigation is needed to elucidate CASC19's precise mechanisms in disease pathogenesis.